Renaissance Capital logo

IPO News & Commentary

Get the latest insights on new stocks

US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO

AKTS

Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more

Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO

Eikon Therapeutics logo

Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size is likely a placeholder for an offering that we estimate...read more

IPO News By Industry

Be the in-house IPO Expert

Our clients are focused on catalyzing growth and creating value.

Not scouring the web for IPO data.

Get the information you need in minutes, not hours. With IPO Pro, you have the entire US IPO market at your fingertips.